• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Hypogonadism in male patients with metastatic cancer prior to chemotherapy.

作者信息

Chlebowski R T, Heber D

出版信息

Cancer Res. 1982 Jun;42(6):2495-8.

PMID:7074625
Abstract

Gonadal hormonal function was assessed in 44 adult males with disseminated cancer prior to chemotherapeutic treatment of their cancer by determination of plasma testosterone, free testosterone, and luteinizing hormone (LH) levels. Low values for both testosterone (43% decreased) and free testosterone (66% decreased) were seen in this largely malnourished cancer population, in which 82% of patients were less than 90% of ideal body weight. Four patients of serum testosterone and LH were seen: (a) normal testosterone and normal LH (12 cases); (b) normal testosterone and high LH (13 cases), consistent with early primary hypogonadism; (c) low testosterone and high LH (10 cases), consistent with frank primary hypogonadism; (d) low testosterone and normal or low LH (9 cases), consistent with secondary hypogonadism. Significantly decreased ideal body weight was found in the group with low testosterone and low or normal LH level. We conclude that decreased gonadal hormone secretion is frequently seen in adult males with advanced cancer and malnutrition even prior to chemotherapy treatment.

摘要

相似文献

1
Hypogonadism in male patients with metastatic cancer prior to chemotherapy.
Cancer Res. 1982 Jun;42(6):2495-8.
2
Hypogonadism in male patients with cancer.男性癌症患者的性腺功能减退
Cancer. 2006 Jun 15;106(12):2583-91. doi: 10.1002/cncr.21889.
3
Risk of hypogonadism from scatter radiation during pelvic radiation in male patients with rectal cancer.男性直肠癌患者盆腔放疗期间散在辐射导致性腺功能减退的风险。
Int J Radiat Oncol Biol Phys. 2009 Aug 1;74(5):1481-6. doi: 10.1016/j.ijrobp.2008.10.011. Epub 2009 Jan 13.
4
Evidence for hypogonadism in massively obese males due to decreased free testosterone.由于游离睾酮降低,大量肥胖男性存在性腺功能减退的证据。
Horm Metab Res. 1981 Nov;13(11):639-41. doi: 10.1055/s-2007-1019359.
5
Primary testicular failure in Klinefelter's syndrome: the use of bivariate luteinizing hormone-testosterone reference charts.克兰费尔特综合征中的原发性睾丸功能衰竭:双变量促黄体生成素 - 睾酮参考图表的应用
Clin Endocrinol (Oxf). 2007 Feb;66(2):276-81. doi: 10.1111/j.1365-2265.2006.02722.x.
6
Hormonal predictors of prostate cancer.前列腺癌的激素预测指标
Urol Int. 2007;79(1):13-8. doi: 10.1159/000102906.
7
Alterations in hormone levels after adjuvant chemoradiation in male rectal cancer patients.男性直肠癌患者辅助放化疗后激素水平的变化
Int J Radiat Oncol Biol Phys. 2009 Jul 15;74(4):1186-90. doi: 10.1016/j.ijrobp.2008.09.027. Epub 2008 Dec 25.
8
Time course of serum testosterone and luteinizing hormone levels after cessation of long-term luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.前列腺癌患者长期使用促黄体生成素释放激素激动剂治疗停止后血清睾酮和促黄体生成素水平的时间进程。
Prostate. 2006 Mar 1;66(4):439-44. doi: 10.1002/pros.20341.
9
[Etiological, clinical and hormonal characteristics of a group of patients with permanent hypogonadism].[一组永久性性腺功能减退患者的病因、临床及激素特征]
An Esp Pediatr. 1997 May;46(5):447-54.
10
Testosterone and gonadotropin levels in men with dementia.患有痴呆症男性的睾酮和促性腺激素水平。
Neuro Endocrinol Lett. 2003 Jun-Aug;24(3-4):203-8.

引用本文的文献

1
Cancer Cachexia.癌症恶病质
Adv Exp Med Biol. 2025;1478:285-314. doi: 10.1007/978-3-031-88361-3_12.
2
Exercise as a therapy for cancer-induced muscle wasting.运动作为癌症引起的肌肉萎缩的一种治疗方法。
Sports Med Health Sci. 2020 Dec 3;2(4):186-194. doi: 10.1016/j.smhs.2020.11.004. eCollection 2020 Dec.
3
Androgen replacement therapy for cancer-related symptoms in male: result of prospective randomized trial (ARTFORM study).雄激素替代疗法治疗男性癌症相关症状:前瞻性随机试验(ARTFORM 研究)结果。
J Cachexia Sarcopenia Muscle. 2021 Aug;12(4):831-842. doi: 10.1002/jcsm.12716. Epub 2021 May 24.
4
Luteinizing Hormone Levels Relate to the Unfavorable Pathology of Prostate Cancer.促黄体生成素水平与前列腺癌的不良病理相关。
J Clin Med. 2020 Apr 29;9(5):1281. doi: 10.3390/jcm9051281.
5
A systematic review of opioid effects on the hypogonadal axis of cancer patients.阿系统性综述阿关于阿类阿片阿药物阿对阿癌症阿患者阿性腺阿轴阿的阿影响阿。
Support Care Cancer. 2014 Jun;22(6):1699-704. doi: 10.1007/s00520-014-2195-2. Epub 2014 Mar 15.
6
Association between hypogonadism, symptom burden, and survival in male patients with advanced cancer.性腺功能减退症与晚期癌症男性患者的症状负担和生存的关系。
Cancer. 2014 May 15;120(10):1586-93. doi: 10.1002/cncr.28619. Epub 2014 Feb 27.
7
When and when not to use testosterone for palliation in cancer care.何时以及何时不应在癌症治疗中使用睾丸素进行姑息治疗。
Curr Oncol Rep. 2014 Apr;16(4):378. doi: 10.1007/s11912-014-0378-0.
8
Testosterone replacement for fatigue in hypogonadal ambulatory males with advanced cancer: a preliminary double-blind placebo-controlled trial.雄激素替代治疗低促性腺激素型男性晚期癌症伴疲劳:一项初步的双盲安慰剂对照试验。
Support Care Cancer. 2013 Sep;21(9):2599-607. doi: 10.1007/s00520-013-1832-5. Epub 2013 May 8.
9
Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients.克唑替尼治疗导致男性癌症患者游离睾酮水平降低并出现症状。
Cancer. 2013 Jul 1;119(13):2383-90. doi: 10.1002/cncr.28089. Epub 2013 Apr 12.
10
Cancer cachexia--pathophysiology and management.癌症恶病质——病理生理学和治疗。
J Gastroenterol. 2013 May;48(5):574-94. doi: 10.1007/s00535-013-0787-0. Epub 2013 Mar 20.